Ongoing Studies
No. HIV-NAT Protocol No. International code Title
1 HIV-NAT 006 Adult cohort A long-term post study follow-up for HIV-infected patients previously participate in HIV-NAT study protocols
2 HIV-NAT 015 Ped cohort Treatment outcome of children with HIV infection
3 HIV-NAT 027 SQV Efficacy and safety of saquinavir based regimen in HIV-1 infected Thai patients who have chronic IDV associated nephrotoxicity
4 HIV-NAT 031 SQV/r polymorphism Study of Genetic Polymorphisms of CYP 3A and MDR-1 genes in Thai HIV-1 infected Patients on Saquinavir/Ritonavir
5 HIV-NAT 032 HIV-HBV immunology Generation of HBV-specific T-cell immunity in individuals with HIV/HBV co-infection receiving HBV-active antiretroviral therapy
6 HIV-NAT 033 TB/HIV A 48 week, randomized, open-label, 2 arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after initiating rifampin containing antituberculous therapy
7 HIV-NAT 035 PREDICT Or CIPRA An open label, randomized study to compare antiretroviral therapy (ART) initiation when CD4+ is between15-24% to ART initiation when CD4+ falls below 15% in children with HIV infection and moderate immune suppression
8 HIV-NAT 035.1 Neuro sub-study of PREDICT A neurodevelopment sub-study of PREDICT: The effect of immediate versus deferred antiretroviral initiation on neurodevelopment in children with HIV in Cambodia and Thailand
9 HIV-NAT 036 Anti-HBc The efficacy of HBV vaccine response and prevalence of Occult HBV infection in isolated anti HBc between HIV infected and HIV un-infected Thai patients
10 HIV-NAT 038 SQV+RTV  Bio-equivalence study of generic GPO saquinavir and Norvir? versus Invirase? and Norvir? in Thai healthy volunteers
11 HIV-NAT 040 NCI Prevalence and risk factors of HIV-associated neurocognitive impairment and psychiatric comorbidities in HIV-1 infected Thai individuals with undetectable viral load in the HAART era.
12 HIV-NAT 041 SQV/TDF Pharmacokinetic and efficacy of Saquinavir mesylate film coated tablet / ritonavir 1500/100 plus Tenofovir/emtricitabine 300/200 mg once daily in HIV pretreated patients : (Sub study of HIV-NAT006: A long-term follow-up study for HIV-infected patients participated in HIV-NAT study protocols.)
13 HIV-NAT 042 BITE A Randomised, Double-blind, Controlled Study on the Effect of One Year Administration of a Nutritional Concept on Immunological Status in HIV-1 Positive Adults not on Antiretroviral Therapy
14 HIV-NAT 043 SARA The Pharmacokinetics of SAquinavir (Invirase new tablet formulation) 1,000 mg + Ritonavir (Norvir) 100 mg q 12 h in HIV-NAT-infected pregnAnt women (SARA).
15 HIV-NAT 044 (bPI) A Pilot study of the pharmacokinetics and safety of ritonavir-boosted indinavir 600/100mg bid combined with nucleoside analogue reverse transcriptase inhibitors in antiretroviral na?ve HIV/TB co-infected patients receiving rifampicin containing anti-tuberculosis therapy
16 HIV-NAT 045 Kaletra low dose Pharmacokinetics and efficacy of low-or standard-dose of lopinavir/ritonavir (Kaletra?) in PI-na?ve HIV-1 infected children
17 HIV-NAT 060 TMC125-C206 A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options
18 HIV-NAT 062  TMC278-C204 A Phase IIb, randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subject
19 HIV-NAT 063  TMC114-C214 A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.
20 HIV-NAT 064 VACCINE  OR HVDDT-N01-AI-05395 AE A Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS – HIV – AE (DNA) Prime and rFPV – HIV – AE Boost HIV Vaccination Strategy
21 HIV-NAT 065 ESPRIT A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2(Proleukin?) in Patients With HIV-1 Infection and CD4+ Cell Counts > 300/mm3 :Evaluation of Subcutaneous Proleukin? in a Randomized International Trial(ESPRIT)
22 HIV-NAT 065.1 TOXIL-2 An open-label, randomized study comparing the uptake of rIL-2 in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT: Toxicity substudy of ESPRIT (TOXIL-2)
23 HIV-NAT 066  PENTA 11 Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial
24 HIV-NAT 067 TMC114-C211:ARTIMIS  A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ ritonavir in treatment-na?ve HIV-1 infected subjects
25 HIV-NAT 068 STALWART:ESPRIT002 A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and CD4+ Cell Counts > 300/mm3 : Study of Aldesleukin with and without Antiretroviral Therapy (ESPRIT 002: STALWART)
26 HIV-NAT 069 BI1100.1452 A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients who have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 Weeks of Nevirapine Therapy
27 HIV-NAT 070 TMC125-C217 An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216)
28 HIV-NAT 072 The Altair Study A Randomised Open-Label Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens (Truvada, efavirenz, zidovudine, Atazanavir, ritonavir and abacavir) as Initial Therapy for HIV Infection
29 HIV-NAT 072.1 The MRS sub-study of Altair THE MRS SUB STUDY: A Randomised Open-Label Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection
30 HIV-NAT 076 Death Study 10 Years Mortality and Disease Progression Analysis of HIV-infected Patients in HIV-NAT Long Term Cohort
31 HIV-NAT 077 Mono PI Simplifying antiretroviral treatment in virally suppressed children by switching from dual boosted lopinavir/ritonavir/saquinavir to lopinavir/ritonavir monotherapy
32 HIV-NAT 078 MET-THAI Motivation Enhancement Therapy for Health Risk Behaviors in HIV+ Thai Youth
33 HIV-NAT 080 TApHOD The TREAT Asia Paediatric HIV Observational Database
34 HIV-NAT 082 Adherence Predictors and outcome assessment of adherence to antiretroviral medications in Thailand, as a resource constrained setting in Asia
35 HIV-NAT 083 RTV low dose Pharmacokinetics of low dose Ritonavir in Thai Patients on a Saquinavir 1500 mg based HAART Regimen
36 HIV-NAT 084 BI:1182.71/POTENT A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista? (Darunavir, DRV/r) in  three-class (NRTI, NNRTI, and PI) treatment-experienced patients with resistance to more than one PI.
37 HIV-NAT 086 Single Vs Dual Boosted PI Comparing the efficacy and safety of single versus double ritonavir-boosted protease inhibitor (PI)-based antiretroviral therapy (ART) regimens for children failing non nucleoside reverse transcriptase inhibitor (NNRTI)-based treatment
38 HIV-NAT010.1 Iron study Change in iron status in HIV-infected children with moderate immune suppression
39 HIV-NAT064.1 Social Impact Evaluate Social impact of preventive HIV vaccine clinical trial in participation
40 HIV-NAT064.2 Circumstances pertaining to participant in Vaccine Trial          Qualitative study on circumstances pertaining to participation in a Preventive HIV Vaccine Clinical Trial (Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccination) 
41 HIV-NAT079 HIVSTAR The HIV Second-line Therapy AntiRetroviral study in patients who failed NNRTI-based regimens
42 HIV-NAT079-01 HIVSTAR-Neurology compartment Effect of HIV and antiretroviral therapy on central nerves system in subjects treated with Lopinavir/ritonavir monotherapy VS 2NRTI plus lopinavir/ritonavir: substudy of HIVSTAR ;Neurology compartment
43 HIV-NAT079-02 HIVSTAR-Genital compartment Effect of HIV and antiretroviral therapy on genital compartment in subjects treated with Lopinavir/ritonavir monotherapy VS 2NRTI plus lopinavir/ritonavir: substudy of HIVSTAR 
44 HIV-NAT087 MK-0518 Early Access of MK-0518 in Combination with an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients with Limited to No Treatment Options
45 HIV-NAT088 AVX-301  A phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V/I mutation in reverse transcriptase
46 HIV-NAT089 TMC114-TiDP31-C229 A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early triatment-experienced HIV-1 infected subjects
47 HIV-NAT092 longitudinal HIV/HBV Cohort Liver disease and HIV/HBV coinfection in the era of HAART:A prospective longitudinal cohort, Thailand
48 HIV-NAT093 Lopinavir/ritonavir in Pregnant women The Pharmacokinetics and Safety of Generic Lopinavir/ritonavir (200/50 mg tablets) 400/100 mg q12h in Thai HIV-infected Pregnant Women
49 HIV-NAT095 TDM Therapeutic Drug Monitoring of generic lopinavir/ritonavir tablets 200/50 mg in the Thai HIV-infected Patient
50 HIV-NAT096 NV20911 A phase I/II study of Invirase boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old.
 
 
Copyrights 2006 HIV-NAT. All rights reserved